Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EORTC Groups Annual Meeting (EGAM) 2019 /
Gynaecological cancer: Where are we now?

14th - 15th Mar 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.03.19
Views: 535

Dr Nelleke Ottevanger - Radboud University Medical Center, Nijmegen, Netherlands

Dr Nelleke Ottevanger speaks to ecancer at the 2019 EORTC Groups Annual Meeting about the discussions that took place in the EORTC's Gynecological Cancer Group meeting.

Dr Ottevanger highlights the competition that surrounds gynaecological research currently and the difficulty to conduct investigator initiative trials.

She also mentions the development of a novel progesterone inhibitor for endometrial cancer and low-grade ovarian cancer.

For the future, Dr Ottevanger and her group would like to focus on the maintenance treatment of hormone receptor-positive endometrial and ovarian cancer, in combination with a CDK4/6 inhibitor. In addition to this, the group would also like to develop a PIK3-CA inhibitor for these types of cancer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation